Get the Stockscreener App
4.75
5.32%
0.24
Pre-market:
4.65
-0.10
-2.11%
Opus Genetics Inc stock is traded at $4.75, with a volume of 387.52K.
It is up +5.32% in the last 24 hours and up +35.71% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
See More
Previous Close:
$4.51
Open:
$4.585
24h Volume:
387.52K
Relative Volume:
0.44
Market Cap:
$337.96M
Revenue:
$14.20M
Net Income/Loss:
$-49.59M
P/E Ratio:
-5.6387
EPS:
-0.8424
Net Cash Flow:
$-35.25M
1W Performance:
+1.93%
1M Performance:
+35.71%
6M Performance:
+176.16%
1Y Performance:
+320.35%
1-Day Range:
$4.56
$4.79
1-Week Range:
$4.3203
$4.79
52-Week Range:
$0.65
$5.30
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.75 | 337.96M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | Oppenheimer | Outperform |
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Sahm
Loss Report: Will Opus Genetics Inc benefit from current market trends2026 Bull vs Bear & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Opus Genetics (IRD) 2026 proxy seeks director votes and doubling of authorized shares - Stock Titan
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch - TipRanks
Abu Dhabi launches UAE’s first gene therapy clinical trial - TradingView
Fed Meeting: Is Opus Genetics Inc attractive for institutional investorsCPI Data & AI Driven Price Forecasts - baoquankhu1.vn
Opus Genetics (IRD) to Release Earnings on Monday - MarketBeat
Gains Report: Is Opus Genetics Inc a strong growth stock2026 Analyst Calls & Technical Pattern Based Signals - baoquankhu1.vn
OCUP SEC FilingsOcuphire Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Opus Genetics COO Schachle sells $19,525 in stock By Investing.com - Investing.com India
Opus Genetics, Inc. (IRD) reports Q4 loss, tops revenue estimates - MSN
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells 2,816 Shares of Stock - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells $19,041.28 in Stock - MarketBeat
Opus Genetics COO Schachle sells $19,525 in stock - Investing.com
Insider Selling: Opus Genetics (NASDAQ:IRD) CEO Sells 24,438 Shares of Stock - MarketBeat
Opus Genetics chief scientific officer sells $19k in stock - Investing.com
Opus Genetics (IRD) COO covers tax withholding via 3,719-share sale - Stock Titan
Opus Genetics (IRD) officer has 2,816 shares sold to cover tax - Stock Titan
Opus Genetics (IRD) CEO has shares sold automatically to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CSO has shares sold automatically for tax withholding - Stock Titan
Aug Catalysts: Can Opus Genetics Inc reach all time highs this yearMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Oppenheimer initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Up 17.9% in February - MarketBeat
[144] Opus Genetics, Inc. SEC Filing - Stock Titan
Opus Genetics (IRD) Initiates Coverage with Outperform Rating by Oppenheimer | IRD Stock News - GuruFocus
Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD) - MarketBeat
Oppenheimer Analyst Initiates Coverage on Opus Genetics (IRD) wi - GuruFocus
Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
There's Reason For Concern Over Opus Genetics, Inc.'s (NASDAQ:IRD) Massive 26% Price Jump - 富途牛牛
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Biotechnology company Opus Genetics Inc recently filed documents with the U.S. Securities and Exchange Commission (SEC) to officially register 7.4 million shares of common stock for secondary market resale. - Bitget
[S-3] Opus Genetics, Inc. Shelf Registration Statement | IRD SEC FilingForm S-3 - Stock Titan
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
HC Wainwright Has Negative View of Opus Genetics Q1 Earnings - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Opus Genetics - MarketBeat
BTIG raises its price target on Opus Genetics, Inc. (IRD) to $12 from $7 and maintains a buy rating - MSN
Opus Genetics, Inc. 2025 Annual Report: Gene Therapy Pipeline, Clinical Progress, and Strategic Partnerships in Ophthalmology - Minichart
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Opus Genetics (NASDAQ:IRD) Given New $10.00 Price Target at Wedbush - MarketBeat
Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Chardan Capital Analyst Says - MarketBeat
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Chardan Capital Raises Price Target for Opus Genetics (IRD) to $11 | IRD Stock News - GuruFocus
Opus Genetics (IRD) Gets a Buy from H.C. Wainwright - The Globe and Mail
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Insider Monkey
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target By Investing.com - Investing.com India
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target - Investing.com Australia
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):